一般演題（口演）15 EGFR遺伝子変異陽性肺癌（臨床試験）

[O15-1] RELAY+：Overall Survival with Ramucirumab+Gefitinib in Untreated EGFR-Mutated Metastatic NSCLC

^○Makoto Nishio¹, Takashi Seto², Martin Reck³, Edward B. Garon⁴, Kazuto Nishio⁵, Kazuo Kasahara⁶, Kazumi Nishino⁷, Miyako Satouchi⁸, Kiyotaka Yoh⁹, Hidetoshi Hayashi¹⁰, Kazuko Sakai⁵, Sotaro Enatsu¹¹, Tomoko Matsui¹¹, Sunoj Chacko Varughese¹², Michelle Carlsen¹³, Carla M. Visseren-Grul¹⁴, Kazuhiko Nakagawa¹ (1.Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, 2.Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, 3.Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany, 4.David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, USA, 5.Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan, 6.Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan, 7.Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan, 8.Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan, 9.Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 10.Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan, 11.Eli Lilly Japan K.K., Kobe, Japan, 12.Statistics, Eli Lilly Services India Pvt. Ltd., Bengaluru, India, 13.Eli Lilly and Company, Indianapolis, USA, 14.Eli Lilly Netherlands, Utrecht, The Netherlands)